kristoff@NET.BIO.NET (Dave Kristofferson) (10/11/89)
Vol. 18, No. 35, October 6, 1989
DATED ANNOUNCEMENTS (RFPs AND RFAs)
STUDY OF STEROID CONTRACEPTIVES AND NEOPLASIA (Sources Sought) .(84/118)..... 1
National Institute of Child Health and Human Development
Index: CHILD HEALTH, HUMAN DEVELOPMENT
THE ROLE OF THE PLACENTA IN TRANSMISSION AND TREATMENT OF HIV
INFECTION IN THE NEWBORN (RFA) ......................(121/177, 324/552)...... 1
National Institute of Child Health and Human Development
Index: CHILD HEALTH, HUMAN DEVELOPMENT
ONGOING PROGRAM ANNOUNCEMENTS
NATIONAL RESEARCH SERVICE AWARDS FOR INSTITUTIONAL RESEARCH TRAINING
IN HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION ACQUIRED
IMMUNODEFICIENCY SYNDROME (AIDS) .........................(183/230).......... 2
Alcohol, Drug Abuse, and Mental Health Administration
Index: ALCOHOL, DRUG ABUSE, MENTAL HEALTH
NATIONAL RESEARCH SERVICE AWARDS FOR INDIVIDUAL FELLOWS IN HUMAN
IMMUNODEFICIENCY VIRUS (HIV) INFECTION ACQUIRED IMMUNODEFICIENCY
SYNDROME (AIDS) ..........................................(241/286).......... 3
Alcohol, Drug Abuse, and Mental Health Administration
Index: ALCOHOL, DRUG ABUSE, MENTAL HEALTH
DATED ANNOUNCEMENTS (RFPs AND RFAs)
STUDY OF STEROID CONTRACEPTIVES AND NEOPLASIA
SOURCES SOUGHT SYNOPSIS: NICHD Contract N01-HD-52901
P.T. 34; K.W. 0750020, 0760085, 0715035, 0755018
National Institute of Child Health and Human Development
The National Institute of Child Health and Human Development is planning to
negotiate an increase in the requirements of contract N01-HD-52901 with the
Fred Hutchinson Cancer Research Center, Seattle, Washington, using other than
full and open competition. The contract currently involves the initial
analysis and interpretation of data from the World Health Organization Study
of Neoplasia and Steroid Contraceptives (WHO Study), on the relationship
between the use of oral contraceptives and other steroid contraceptives
(primarily depo-medroxyprogesterone acetate), and the occurrence in women of
cancer of the breast and reproductive tract, i.e., the endometrium, ovary and
cervix. The Government intends to expand the data analysis efforts to include
additional analyses of this data set for topics of interest. The effort
involved is expected to require approximately 3 person-years. The
determination to use other than full and open competition will be made in
accordance with 41 USC 253 (c) (1) as set forth in FAR 6.302-1. The proposed
source, by virtue of their understanding and utilization of this data during
the course of the current contract, has developed the expertise and has sole
access to the WHO Study data. The purpose of this synopsis is to determine
whether there are other sources with the requisite qualifications to perform
the work described above. Organizations who believe they are qualified to
perform this shall provide capability statements within 45 days of publication
of this synopsis to the following address:
Contracts Management Section, NICHD
National Institutes of Health
Executive Plaza North, Room 610
6130 Executive Boulevard
Rockville, Maryland 20852
THE ROLE OF THE PLACENTA IN TRANSMISSION AND TREATMENT OF HIV INFECTION
IN THE NEWBORN
RFA AVAILABLE: 89-HD-10
P.T. 34; K.W. 1002034, 0413002, 0715008, 0715125, 0403020, 0710070
National Institute of Child Health and Human Development
Application Receipt Date: January 17, 1990
The National Institute of Child Health and Human Development (NICHD) invites
grant applications to support basic research on the role of the placenta in
transmitting infection from mother to infant and its role in potential in
utero therapies for HIV infection. The research areas may include but are not
limited to: (1) leucocyte antigen immunohistochemistry, in situ hybridization
and electron microscopy of the placenta to identify virus infected cells or
other cells that may be infected by HIV and/or play a role in transport of the
virus from mother to infant; these tests should be correlated with newborn HIV
infection to determine the predictive value of viral antigen detection; (2)
studies of the role of maternal antibody(ies) in blocking the transmission of
HIV infection from mother to infant; (3) leucocyte antigen
immunohistochemistry, in situ hybridization and electron microscopy of the
products of conception to understand the timing of fetal exposure to HIV and
determine the risk of fetal infection; (4) studies of the pharmacokinetics of
antiretroviral and other chemotherapeutic agents across the placenta to the
fetus to determine the success of transport, efficacy and risk of
teratogenesis; (5) gross morphologic and histologic analyses of the effect of
HIV infection on placental development and function.
Inclusion of women and minorities are encouraged. If they are excluded,
reasons for this exclusion must be included in the application.
MECHANISM OF SUPPORT
Support will be available through the traditional research grant (RO1).
Support for grants is contingent upon receipt of appropriated funds. It is
anticipated that four to six meritorious applications will be funded.
Vol. 18, No. 35, October 6, 1989 - Page 1
APPLICATION PROCEDURE
Application must be submitted on form PHS 398 (revised 10/88).
ADDITIONAL INFORMATION
Potential applicants are encouraged to request further information by
telephoning:
Pamela Stratton, M.D.
Pediatric, Adolescent, and Maternal AIDS Branch
Center for Research for Mothers and Children
National Institute of Child Health and Human Development
EPN, Room 630-P
6130 Executive Boulevard
Rockville, Maryland 20892
Telephone: (301) 496-7339
ONGOING PROGRAM ANNOUNCEMENTS
NATIONAL RESEARCH SERVICE AWARDS FOR INSTITUTIONAL RESEARCH TRAINING IN HUMAN
IMMUNODEFICIENCY VIRUS (HIV) INFECTION ACQUIRED IMMUNODEFICIENCY SYNDROME
(AIDS)
P.T. 44; K.W. 0715008, 0720005, 0404003, 0404009, 0715095
Alcohol, Drug Abuse, and Mental Health Administration
The National Institute on Drug Abuse (NIDA) is initiating a new program in
AIDS and HIV-related research and along with the National Institute of Mental
Health (NIMH) and the National Institute on Alcohol Abuse and Alcoholism
(NIAAA), seek applications for research training in the areas of mental
health, alcoholism and drug abuse as related to the HIV syndrome. The
applicant institution must have the staff and facilities to conduct the
proposed research training and in a suitable environment for performing high
quality work. Awards for institutional grants may be made for project periods
of up to five years. In FY l990, a total of $600,000 (NIDA), $2,507,000
(NIMH), and $338,000 (NIAAA) will be available for institutional and
individual NRSAs related to HIV. Availability and amount of funds for future
years are contingent upon annual appropriations. NIDA, NIMH, and NIAAA will
accept applications in response to this announcement under the Public Health
Service receipt dates for NRSA applications: May 10, September 10, January
10. Potential applicants may also wish to see the NIDA/NIMH/NIAAA
announcement in this issue for individual fellowships. Potential applicants
interested in obtaining further information should contact:
Charles Sharp, Ph.D.
Chairman, Fellowship/Training
National Institute on Drug Abuse
Room l0A-31
Telephone: (301) 443-6300
Ellen S. Stover, Ph.D.
AIDS Coordinator
National Institute of Mental Health
Room 17C-04
Telephone: (301) 443-7281
David Lozosky, M.D., Ph.D.
AIDS Coordinator
National Institute on Alcohol Abuse and Alcoholism
Room l4C-20
Telephone: (301) 443-4223
The mailing address for all of the above is:
5600 Fishers Lane
Rockville, Maryland 20857
Vol. 18, No. 35, October 6, 1989 - Page 2
NATIONAL RESEARCH SERVICE AWARDS FOR INDIVIDUAL FELLOWS IN HUMAN
IMMUNODEFICIENCY VIRUS (HIV) INFECTION ACQUIRED IMMUNODEFICIENCY SYNDROME
(AIDS)
P.T. 22; K.W. 0715008, 0720005, 0404003, 0404009, 0715095
Alcohol, Drug Abuse, and Mental Health Administration
The National Institute on Drug Abuse (NIDA) is initiating a new program in
AIDS- and HIV-related research and along with the National Institute of Mental
Health (NIMH) and the National Institute on Alcohol Abuse and Alcoholism
(NIAAA), seek applications for research training in the areas of mental
health, alcoholism and drug abuse as related to the HIV syndrome. Applicants
must propose research training in specified areas and demonstrate that the
proposed program offers them an opportunity to use and enhance their skills
and knowledge. In FY l990, a total of $600,000 (NIDA), $2,507,000 (NIMH), and
$338,000 (NIAAA) will be available for institutional and individual NRSAs
related to HIV. Availability and amount of funds for future years are
contingent upon annual appropriations. NIDA, NIMH, and NIAAA will accept
applications in response to this announcement under the Public Health Service
receipt dates for NRSA applications: May 10, September 10, January 10.
Potential applicants interested in obtaining further information should
contact:
Charles Sharp, Ph.D.
Chairman, Fellowship/Training
National Institute on Drug Abuse
Room l0A-31
Telephone: (301) 443-6300
Ellen S. Stover, Ph.D.
AIDS Coordinator
National Institute of Mental Health
Room 17C-04
Telephone: (301) 443-7281
David Lozosky, M.D., Ph.D.
AIDS Coordinator
National Institute on Alcohol Abuse and Alcoholism
Room l4C-20
Telephone: (301) 443-4223
The mailing address for all of the above is:
5600 Fishers Lane
Rockville, Maryland 20857
Vol. 18, No. 35, October 6, 1989 - Page 3
FULL TEXT OF RFAs FOR ONLINE ACCESS
THE ROLE OF THE PLACENTA IN TRANSMISSION AND TREATMENT OF
HIV INFECTION IN THE NEWBORN
RFA-89-HD-10
P.T. 34; K.W. 1002034, 0413002, 0715008, 0715125, 0403020, 0710070
National Institute of Child Health and Human Development
Application Receipt Date: January 17, 1990
PURPOSE
The National Institute of Child Health and Human Development
(NICHD) invites grant applications to support basic research
on the role of the placenta in transmitting infection from
mother to infant and its role in potential in utero
therapies for HIV infection. The research areas may include
but are not limited to: (1) leucocyte antigen
immunohistochemistry, in situ hybridization and electron
microscopy of the placenta to identify virus infected cells
or other cells that may be infected by HIV and/or play a
role in transport of the virus from mother to infant; these
tests should be correlated with newborn HIV infection to
determine the predictive value of viral antigen detection;
(2) studies of the role of maternal antibodies in blocking
the transmission of HIV infection from mother to infant; (3)
leucocyte antigen immunohistochemistry, in situ
hybridization and electron microscopy of the products of
conception to understand the timing of fetal exposure to HIV
and determine the risk of fetal infection; (4) studies of
the pharmacokinetics of antiretroviral and other
chemotherapeutic agents across the placenta to the fetus to
determine the success of transport, efficacy and risk of
teratogenesis; (5) gross morphologic and histologic analyses
of the effect of HIV infection on placental development and
function. NICHD encourages all proposals which in any way
scientifically examine and define the role of the placenta
in transmission of HIV infection from mother to fetus or the
role of the placenta in the in utero treatment of HIV
infection in the fetus.
DISCIPLINES AND EXPERTISE
Among the relevant expertise and disciplines that may be
appropriate for inclusion in this program are: obstetrics,
obstetric infectious disease, virology, immunology,
pathology, pediatrics, cell biology and pharmacology.
ADMINISTRATIVE BACKGROUND
The Pediatric, Adolescent and Maternal AIDS (PAMA) Branch of
NICHD supports research on the epidemiology, natural
history, pathogenesis, clinical manifestations, and
treatment of HIV infection [including acquired
immunodeficiency syndrome (AIDS)] in pregnant women,
neonates, infants, children and adolescents. The Center for
Research for Mothers and Children (the program of NICHD in
which the PAMA Branch is located) held a conference on
Research Issues in Pediatric HIV disease in 1988. One of
the areas of research interest identified at that conference
was the role of the placenta in transmission to and
treatment of HIV infection in the fetus. In particular,
little information exists on the mechanism for transmission
of the virus from mother to fetus and the transport of drugs
potentially useful in HIV therapeutics across the placenta.
The PAMA Branch seeks to strengthen the research effort
directed to a better understanding of the role of the
placenta in the transmission and treatment of HIV infection.
RESEARCH SCOPE
The general scope of research considered by this Request for
Applications (RFA) is delineated above in the PURPOSE
section. Research on other entities or concepts not
previously mentioned that may be involved in elucidating the
role of the placenta in transmission and treatment of HIV
infection may be included in this RFA.
--Special requirements may be necessary for some of these
studies to follow and confirm HIV infection in children born
to HIV infected women.
--Collaboration with ongoing studies of maternal-fetal
transmission are encouraged where possible and useful.
ASSIGNMENT OF APPLICATIONS
All grant applications will be received by the Division of
Research Grants (DRG) and assigned to NICHD by the staff of
DRG.
MECHANISM OF SUPPORT
Support for this program will be through the traditional
research grant (R01). Policies that govern grant-in-aid
award programs of the Public Health Service will prevail.
The support of grants pursuant to this RFA is contingent
upon ultimate receipt of appropriated funds for this
purpose. The number of awards will be influenced by the
overall merit of the proposals, by their relevance to
program goals, and by the amount of funds available to the
Institute. It is anticipated that four to six meritorious
applications will be funded.
After the awarded projects are underway, meetings meant to
foster communication and sharing of information of work in
progress will be held. Principal and co-investigators will
be encouraged to attend one two-day meeting per year in
Bethesda, MD, and funds for that purpose should be included
in the application's budget.
REVIEW CRITERIA AND PROCEDURES
Applications will be reviewed by NICHD for responsiveness to
the scope of the RFA. Non-responsive applications will be
returned to the applicant. In those cases, the applicant
may resubmit the application to DRG and have it assigned as
any other unsolicited grant application during the next
review cycle. An application will also be considered
non-responsive to the RFA if it is identical to one already
submitted to NIH for review, unless the previous application
is withdrawn.
Responsive applications to the RFA will be reviewed within
six months of receipt. They may be subjected to a triage by
a peer-review group to determine their scientific merit
relative to other applications received in response to this
RFA. After the triage, NIH will withdraw from competition
those applications judged to be noncompetitive and notify
the applicant and institutional grant official.
Applications judged to be competitive, however, will be
evaluated for scientific/technical merit by a review panel
convened solely for this purpose by the Scientific Review
Program, NICHD. Inclusion of women and minorities are
encouraged. If they are excluded, reasons for this
exclusion must be included in the application.
Criteria for the initial review include:
*the significance and originality of research goals and
approaches;
*the feasibility of research and adequacy of experimental
design;
*the research experience and competence of the
investigator(s) to conduct the proposed work;
*the adequacy of investigator's effort devoted to the
project;
*the appropriateness of the project duration and cost
relative to the work proposed.
Following review by the Initial Review Group, applications
will be evaluated by the Institute's Advisory Council for
program relevance and policy issues before awards are made.
After scientific review, other Institutes may participate in
co-funding meritorious applications received in response to
this RFA.
The anticipated award date is July 1, 1990.
METHOD OF APPLYING
Applications should be submitted on form PHS-398 (revised
10/88) which is available in most institutional business
offices or from the Division of Research Grants, NIH
(301/496-7441). Applications should be identified by
checking the "yes" box in Item 2 of the face page of the
application and typing in the words, "In Response to RFA
89-HD-10". THE RFA LABEL AVAILABLE IN FORM 398 MUST BE
AFFIXED TO THE BOTTOM OF THE FACE PAGE OF THE ORIGINAL
APPLICATION. The signed original (topmost) and twenty (20)
copies of the application must be received by the Division
of Research Grants by January 17, 1990.
Applications should be sent or delivered to:
Division of Research Grants
AIDS Coordinator
National Institutes of Health
Westwood Building, Room 9
5333 Westbard Avenue
Bethesda, MD 20892
Also send three copies to:
Laurance S. Johnston, Ph.D.
Deputy Director, Scientific Review Program
National Institute of Child Health and Human Development
Executive Plaza North, Room 520
Bethesda, Maryland 20892
Applications must be received by January 17, 1990.
Late applications will not be accepted.
TIMETABLE
Application Receipt Date: January 17, 1990
Initial Review Date: March 1990
Review by NICHD Advisory Council: June 1990
Anticipated Award Date: July 1, 1990
Inquiries regarding this announcement may be directed to:
Pamela Stratton, M.D.
Special Assistant for Obstetrics
Pediatric, Adolescent and Maternal AIDS Branch
National Institute of Child Health and Human Development
Executive Plaza North, Room 630-P
Bethesda, MD 20892
301-496-7339 or 7350
This program is described in the catalog of Federal Domestic
Assistance No. 13.865, Research for Mothers and Children.
Awards will be made under the authority of the Public Health
Service Act, Section 302 (42 USC241), and administered under
PHS grant policies and Federal Regulations 42 CRF Part 52
and 42 CRF Part 74. This program is not subject to review
by a Health Systems Agency.